Moors EHM - Search Results

1

From Mattering to Mattering More: 'Goods' and 'Bads' in Ageing and Innovation Policy Discourses.

Greubel C, Moors EHM, Peine A. Greubel C, et al. Among authors: moors ehm. Int J Environ Res Public Health. 2021 Jul 16;18(14):7596. doi: 10.3390/ijerph18147596. Int J Environ Res Public Health. 2021. PMID: 34300047 Free PMC article.

2

Toward Responsible Artificial Intelligence in Long-Term Care: A Scoping Review on Practical Approaches.

Lukkien DRM, Nap HH, Buimer HP, Peine A, Boon WPC, Ket JCF, Minkman MMN, Moors EHM. Lukkien DRM, et al. Among authors: moors ehm. Gerontologist. 2023 Jan 24;63(1):155-168. doi: 10.1093/geront/gnab180. Gerontologist. 2023. PMID: 34871399 Free PMC article. Review.

3

Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases.

Douglas CMW, Aith F, Boon W, de Neiva Borba M, Doganova L, Grunebaum S, Hagendijk R, Lynd L, Mallard A, Mohamed FA, Moors E, Oliveira CC, Paterson F, Scanga V, Soares J, Raberharisoa V, Kleinhout-Vliek T. Douglas CMW, et al. Orphanet J Rare Dis. 2022 Sep 5;17(1):344. doi: 10.1186/s13023-022-02476-6. Orphanet J Rare Dis. 2022. PMID: 36064440 Free PMC article.

4

How do people understand the spread of COVID-19 infections? Mapping mental models of factors contributing to the pandemic.

de Ridder DTD, van den Boom LATP, Kroese FM, Moors EHM, van den Broek KL. de Ridder DTD, et al. Among authors: moors ehm. Psychol Health. 2022 Oct 3:1-20. doi: 10.1080/08870446.2022.2129054. Online ahead of print. Psychol Health. 2022. PMID: 36193021

5

Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam.

Cao VAT, Nguyen TQ, Le Quyen D, Boon WPC, Moors EHM, Dondorp AM, de Haan F, Amaratunga C. Cao VAT, et al. Among authors: moors ehm. Malar J. 2023 Oct 28;22(1):326. doi: 10.1186/s12936-023-04763-4. Malar J. 2023. PMID: 37898749 Free PMC article. Review.

6

Exploring emerging technologies using metaphors--a study of orphan drugs and pharmacogenomics.

Boon W, Moors E. Boon W, et al. Soc Sci Med. 2008 May;66(9):1915-27. doi: 10.1016/j.socscimed.2008.01.012. Epub 2008 Mar 4. Soc Sci Med. 2008. PMID: 18308439

7

Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.

Boon WP, Moors EH, Meijer A, Schellekens H. Boon WP, et al. Clin Pharmacol Ther. 2010 Dec;88(6):848-53. doi: 10.1038/clpt.2010.207. Epub 2010 Oct 20. Clin Pharmacol Ther. 2010. PMID: 20962774

8

A standardised framework to identify optimal animal models for efficacy assessment in drug development.

Ferreira GS, Veening-Griffioen DH, Boon WPC, Moors EHM, Gispen-de Wied CC, Schellekens H, van Meer PJK. Ferreira GS, et al. Among authors: moors ehm. PLoS One. 2019 Jun 13;14(6):e0218014. doi: 10.1371/journal.pone.0218014. eCollection 2019. PLoS One. 2019. PMID: 31194784 Free PMC article.

9

Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease.

Veening-Griffioen DH, Ferreira GS, van Meer PJK, Boon WPC, Gispen-de Wied CC, Moors EHM, Schellekens H. Veening-Griffioen DH, et al. Among authors: moors ehm. Eur J Pharmacol. 2019 Sep 15;859:172524. doi: 10.1016/j.ejphar.2019.172524. Epub 2019 Jul 7. Eur J Pharmacol. 2019. PMID: 31291566 Free article.

10

In-Hospital Production of Medicines: Preparing for Disruption.

Kalkman S, Arentshorst M, Hoekman J, Boon W, Uijtendaal E, van Thiel G, Moors E. Kalkman S, et al. Trends Biotechnol. 2020 Oct;38(10):1045-1047. doi: 10.1016/j.tibtech.2019.09.011. Epub 2019 Oct 31. Trends Biotechnol. 2020. PMID: 31679825 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page